RxDoctor Payments Data

Jennifer Chiriano

Family · Redlands, CANPI 1801426465

Payments from drug & device makers

$3,794in general payments, 2019–2025

Across 177 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boston Scientific$862
  • Scilex Pharmaceuticals Inc.$207
  • Collegium Pharmaceutical, Inc.$131
  • Biohaven Pharmaceutical Holding Company Ltd.$89
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$48
  • plus $132 from 5 others

What the payments were for

  • Food & beverage$3,794100%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,794 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$73,493
Medicare patients
325
Services billed
1,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl65$54,970
MovantikNaloxegol Oxalate105$41,549
ZtlidoLidocaine42$23,286
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen838$18,765
OxycontinOxycodone Hcl28$17,550
Buprenorphine62$16,141
Lidocaine128$15,953
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen454$14,008
Naloxone Hcl158$10,809
Diclofenac Sodium177$9,405
ButransBuprenorphine18$6,782
Gabapentin525$5,881
Morphine Sulfate ErMorphine Sulfate190$4,470
Oxycodone Hcl166$4,186
Pregabalin197$3,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$131$54,97065 claims
Scilex Pharmaceuticals Inc.Ztlido$207$23,28642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Redlands

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →